[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611428":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":63,"collaborators":66,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":24,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":24,"enrollmentInfo":79,"targetDuration":24,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":37,"whyStopped":24,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"The George Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Aspirin Continuation Group","EXPERIMENTAL","All participants received standard conservative treatment for chronic subdural hematoma, with a randomized intervention to continue aspirin administration. This group of participants received oral administration of aspirin at a dose of 100 mg per day.",[13],"Drug: Aspirin Continuation",{"label":15,"type":10,"description":16,"interventionNames":17},"Aspirin Discontinuation Group","All participants received standard conservative treatment for chronic subdural hematoma, with a randomized intervention to discontinue aspirin administration. This group of participants did not use aspirin during the treatment period.",[18],"Drug: Aspirin Discontinuation",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Aspirin Continuation",[9],null,{"type":21,"name":26,"description":16,"armGroupLabels":27,"otherNames":24},"Aspirin Discontinuation",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Tao Liu, MD","CONTACT","+86-18302204804","TLiu1@georgeinstitute.org.au",[35,50],{"facility":36,"status":37,"city":38,"state":24,"zip":24,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Xuanwu Hospital Capital Medical University","RECRUITING","Beijing","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":49,"role":31,"phone":32,"phoneExt":24,"email":33},"Tao Liu",{"facility":51,"status":37,"city":52,"state":24,"zip":24,"country":39,"countryCode":40,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Tianjin Medical University General Hospital","Tianjin",{"type":42,"coordinates":54},[55,56],117.17667,39.14222,{"lat":56,"lon":55},[59],{"name":60,"role":31,"phone":61,"phoneExt":24,"email":62},"Yu Qian","+86-16622511377","yqian@tmu.edu.cn",{"type":64,"investigatorFullName":49,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","MD",[67,68],{"name":51,"class":6},{"name":69,"class":6},"Xuanwu Hospital, Beijing","100611428","aspirin-continuation-or-discontinuation-in-conservative-treatment-for-chronic-subdural-hematoma-100611428",false,"NCT07240454","Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma","Safety and Efficacy of Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age ≥18 years, male or female;\n* Confirmed diagnosis of chronic subdural hematoma (cSDH) by cranial CT and\u002For MRI;\n* Intended for conservative management (i.e., no surgical evacuation indication at enrollment);\n* Regular aspirin use at enrollment;\n* Informed consent signed by the patient or legal representative.\n\nExclusion Criteria:\n\n* Patients requiring emergency surgery to remove hematoma at enrollment;\n* Concurrent use of other anticoagulants or antiplatelet agents that cannot be discontinued according to the study protocol;\n* cSDH secondary to other diseases or conditions (e.g., excessive drainage from ventriculoperitoneal shunts, intracranial tumors);\n* Active bleeding events or major cardiac events (e.g., acute myocardial infarction, unstable angina, or revascularization surgery) within 30 days prior to enrollment;\n* Known bleeding disorders (e.g., hemophilia, severe thrombocytopenia);\n* Individuals unable to provide informed consent or for whom completion of follow-up is anticipated to be difficult.","ALL","18 Years",{"count":80,"type":81},143,"ESTIMATED","INTERVENTIONAL",[84],"NA","This clinical study aims to learn about the efficacy and safety of aspirin continuation or discontinuation in conservative treatment for chronic subdural hematoma. All participants received standard conservative treatment for chronic subdural hematoma, with a randomized intervention to either continue or discontinue aspirin administration. By participating in this study, participants can receive additional scientific guidance on aspirin medication management beyond routine conservative treatment, thereby optimizing individualized therapy.",[87],"Chronic Subdural Hematoma",[87,89,90,91,92,93,94],"Aspirin","Conservative Treatment","Randomized Clinical Trial","Safety","Efficacy","cSDH","2025-11-16",{"date":97,"type":98},"2025-11-21","ACTUAL",{"date":100,"type":98},"2025-10-15",{"date":102,"type":81},"2028-12",{"name":49,"class":6},2]